Dose dense regimen of 75 mg cyclophosphamide epirubicin. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy3

Bone Marrow Spleen Antilymphocyte Serum

Organisms2

Mice, Inbred BALB C Mice, Inbred Strains

Diseases39

Breast Neoplasms Leukopenia Neutropenia Lymphoma, Non-Hodgkin Alopecia Vomiting Hematologic Diseases Nausea Neoplasm Metastasis Cystitis Recurrence Lymphatic Metastasis Neoplasm Recurrence, Local Neoplasms Lung Neoplasms Adenocarcinoma Stomatitis Wegener Granulomatosis Carcinoma, Small Cell Lupus Nephritis Amenorrhea Disease Progression Stomach Neoplasms Hodgkin Disease Lymphoma Thrombocytopenia Graft vs Host Disease Anemia, Aplastic Lymphoma, Large B-Cell, Diffuse Ovarian Neoplasms Heart Diseases Bone Marrow Diseases Soft Tissue Neoplasms Multiple Myeloma Bone Neoplasms Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms, Second Primary Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Lymphoma, Follicular

Chemicals and Drugs59

Epirubicin Cyclophosphamide Doxorubicin Fluorouracil Vincristine Antibiotics, Antineoplastic Antineoplastic Agents, Alkylating Phosphoramide Mustards Methotrexate Prednisone Paclitaxel Etoposide Granulocyte Colony-Stimulating Factor Taxoids Cisplatin Immunosuppressive Agents Thiotepa Ifosfamide Antineoplastic Agents Busulfan Razoxane Vinblastine Anthracyclines Prednisolone Deoxycytidine Antibodies, Monoclonal, Murine-Derived Vidarabine Carboplatin Mitoxantrone Methylprednisolone Bleomycin Melphalan Carmustine Antibodies, Monoclonal Azathioprine Mesna Cytarabine Antineoplastic Agents, Phytogenic Receptor, erbB-2 Chlorambucil Procarbazine Dexamethasone Leucovorin Vindesine Tamoxifen Antibodies, Monoclonal, Humanized Alkylating Agents Prolyl Hydroxylases Acrolein Antiemetics Recombinant Proteins Antimetabolites, Antineoplastic Daunorubicin Myeloablative Agonists Antilymphocyte Serum Naphthacenes Mechlorethamine Mycophenolic Acid Idarubicin

Analytical, Diagnostic and Therapeutic Techniques and Equipment47

Antineoplastic Combined Chemotherapy Protocols Drug Administration Schedule Treatment Outcome Chemotherapy, Adjuvant Disease-Free Survival Combined Modality Therapy Survival Analysis Infusions, Intravenous Survival Rate Drug Therapy, Combination Remission Induction Pulse Therapy, Drug Neoadjuvant Therapy Neoplasm Staging Follow-Up Studies Hematopoietic Stem Cell Transplantation Administration, Oral Bone Marrow Transplantation Transplantation, Autologous Injections, Intravenous Whole-Body Irradiation Prospective Studies Drug Evaluation Transplantation Conditioning Prognosis Administration, Metronomic Mastectomy, Radical Immunosuppression Retrospective Studies Hematopoietic Stem Cell Mobilization Leukocyte Count Transplantation, Homologous Maximum Tolerated Dose Area Under Curve Clinical Trials as Topic Random Allocation Feasibility Studies Actuarial Analysis Salvage Therapy Kaplan-Meier Estimate Pilot Projects Mastectomy Double-Blind Method Lethal Dose 50 Platelet Count Neoplasm Transplantation Radiotherapy Dosage

Phenomena and Processes13

Dose-Response Relationship, Drug Time Factors Leukocyte Count Maximum Tolerated Dose Area Under Curve Biotransformation Drug Resistance, Neoplasm Drug Synergism Premenopause Drug Interactions Drug Resistance, Multiple Lethal Dose 50 Platelet Count

Information Science1

Health Care15

Treatment Outcome Disease-Free Survival Survival Analysis Survival Rate Follow-Up Studies Prospective Studies Retrospective Studies Area Under Curve Clinical Trials as Topic Random Allocation Feasibility Studies Actuarial Analysis Kaplan-Meier Estimate Pilot Projects Double-Blind Method

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Phenomena and Processes Information Science Health Care

Epirubicin Cyclophosphamide Antineoplastic Combined Chemotherapy Protocols Doxorubicin Drug Administration Schedule Fluorouracil Vincristine Antibiotics, Antineoplastic Breast Neoplasms Treatment Outcome Antineoplastic Agents, Alkylating Phosphoramide Mustards Methotrexate Prednisone Chemotherapy, Adjuvant Paclitaxel Disease-Free Survival Combined Modality Therapy Etoposide Granulocyte Colony-Stimulating Factor Taxoids Cisplatin Immunosuppressive Agents Survival Analysis Dose-Response Relationship, Drug Infusions, Intravenous Survival Rate Leukopenia Drug Therapy, Combination Remission Induction Thiotepa Neutropenia Ifosfamide Pulse Therapy, Drug Antineoplastic Agents Busulfan Razoxane Neoadjuvant Therapy Time Factors Vinblastine Lymphoma, Non-Hodgkin Anthracyclines Prednisolone Deoxycytidine Neoplasm Staging Follow-Up Studies Antibodies, Monoclonal, Murine-Derived Hematopoietic Stem Cell Transplantation Administration, Oral Vidarabine Bone Marrow Transplantation Alopecia Carboplatin Vomiting Hematologic Diseases Transplantation, Autologous Injections, Intravenous Nausea Mitoxantrone Neoplasm Metastasis Whole-Body Irradiation Prospective Studies Drug Evaluation Transplantation Conditioning Methylprednisolone Bleomycin Melphalan Carmustine Prognosis Cystitis Administration, Metronomic Recurrence Mastectomy, Radical Immunosuppression Antibodies, Monoclonal Lymphatic Metastasis Retrospective Studies Azathioprine Hematopoietic Stem Cell Mobilization Neoplasm Recurrence, Local Mesna Neoplasms Leukocyte Count Lung Neoplasms Transplantation, Homologous Cytarabine Antineoplastic Agents, Phytogenic Adenocarcinoma Maximum Tolerated Dose Stomatitis Area Under Curve Biotransformation Clinical Trials as Topic Wegener Granulomatosis Receptor, erbB-2 Carcinoma, Small Cell Lupus Nephritis Random Allocation Amenorrhea Chlorambucil

No FAQ available that match "dose dense regimen of 75 mg cyclophosphamide epirubicin"